Literature DB >> 21925828

Baseline trajectories of heavy drinking and their effects on postrandomization drinking in the COMBINE Study: empirically derived predictors of drinking outcomes during treatment.

Ralitza Gueorguieva1, Ran Wu, Dennis Donovan, Bruce James Rounsaville, David Couper, John Harrison Krystal, Stephanie Samples O'Malley.   

Abstract

The Combined Pharmacotherapies and Behavioral Interventions (COMBINE) Study sought to answer questions about the benefits of combining behavioral and pharmacological interventions (naltrexone and acamprosate) in alcohol-dependent patients. Our goals were to identify trajectories of heavy drinking before randomization in COMBINE, to characterize patients in these trajectories, and to assess whether prerandomization trajectories predict drinking outcomes. We analyzed daily indicators of heavy drinking 90 days before randomization using a trajectory-based approach. Each patient was assigned to the most likely prerandomization heavy-drinking trajectory, and the baseline characteristics of participants in the baseline trajectories were compared. The main and interactive effects of these trajectories and treatment factors (acamprosate, naltrexone, or combined behavioral intervention) on summary drinking measures during active treatment (16 weeks) were assessed. We identified five trajectories of heavy drinking prerandomization: "T1: frequent heavy drinkers"; "T2: very frequent heavy drinkers"; "T3: nearly daily heavy drinkers"; "T4: daily heavy drinkers"; and "T5: daily heavy drinkers stopping early" before randomization. Trajectory membership was significantly associated with all drinking outcomes. Patients in "T5: daily heavy drinkers stopping early" had comparable drinking outcomes to those in "T1: frequent heavy drinkers," whereas the remaining trajectories were associated with significantly worse outcomes. The baseline trajectory did not interact significantly with the treatment condition. These exploratory analyses confirmed the hypothesis that baseline trajectories predict postrandomization drinking outcomes. Interestingly, "T5: daily heavy drinkers stopping early" had outcomes that were comparable to the least severe baseline trajectory "T1: frequent heavy drinkers," and baseline trajectories of heavy drinking did not moderate the treatment effects.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21925828      PMCID: PMC3266454          DOI: 10.1016/j.alcohol.2011.08.008

Source DB:  PubMed          Journal:  Alcohol        ISSN: 0741-8329            Impact factor:   2.405


  40 in total

1.  Measurement and choice of drinking outcome variables in the COMBINE Study.

Authors:  Raymond E Anton; Carrie L Randall
Journal:  J Stud Alcohol Suppl       Date:  2005-07

Review 2.  Assessing nondrinking outcomes in combined pharmacotherapy and psychotherapy clinical trials for the treatment of alcohol dependence.

Authors:  Ron A Cisler; Daniel R Kivlahan; Dennis Donovan; Margaret E Mattson
Journal:  J Stud Alcohol Suppl       Date:  2005-07

3.  Variation in the drinking trajectories of freshmen college students.

Authors:  Paul E Greenbaum; Frances K Del Boca; Jack Darkes; Chen-Pin Wang; Mark S Goldman
Journal:  J Consult Clin Psychol       Date:  2005-04

4.  Rates and predictors of relapse after natural and treated remission from alcohol use disorders.

Authors:  Rudolf H Moos; Bernice S Moos
Journal:  Addiction       Date:  2006-02       Impact factor: 6.526

5.  Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial.

Authors:  James C Garbutt; Henry R Kranzler; Stephanie S O'Malley; David R Gastfriend; Helen M Pettinati; Bernard L Silverman; John W Loewy; Elliot W Ehrich
Journal:  JAMA       Date:  2005-04-06       Impact factor: 56.272

6.  The reliability of Form 90: an instrument for assessing alcohol treatment outcome.

Authors:  J S Tonigan; W R Miller; J M Brown
Journal:  J Stud Alcohol       Date:  1997-07

7.  Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial.

Authors:  Raymond F Anton; Stephanie S O'Malley; Domenic A Ciraulo; Ron A Cisler; David Couper; Dennis M Donovan; David R Gastfriend; James D Hosking; Bankole A Johnson; Joseph S LoCastro; Richard Longabaugh; Barbara J Mason; Margaret E Mattson; William R Miller; Helen M Pettinati; Carrie L Randall; Robert Swift; Roger D Weiss; Lauren D Williams; Allen Zweben
Journal:  JAMA       Date:  2006-05-03       Impact factor: 56.272

Review 8.  Pharmacological treatment of alcohol dependence: target symptoms and target mechanisms.

Authors:  Markus Heilig; Mark Egli
Journal:  Pharmacol Ther       Date:  2006-03-20       Impact factor: 12.310

9.  Matching alcoholism treatments to client heterogeneity: treatment main effects and matching effects on drinking during treatment. Project MATCH Research Group.

Authors: 
Journal:  J Stud Alcohol       Date:  1998-11

10.  The Obsessive Compulsive Drinking Scale: a self-rated instrument for the quantification of thoughts about alcohol and drinking behavior.

Authors:  R F Anton; D H Moak; P Latham
Journal:  Alcohol Clin Exp Res       Date:  1995-02       Impact factor: 3.455

View more
  10 in total

1.  Predictors of abstinence from heavy drinking during treatment in COMBINE and external validation in PREDICT.

Authors:  Karl Mann; Stephanie S O'Malley; Ralitza Gueorguieva; Ran Wu; Patrick G O'Connor; Constance Weisner; Lisa M Fucito; Sabine Hoffmann
Journal:  Alcohol Clin Exp Res       Date:  2014-10       Impact factor: 3.455

Review 2.  Rodent models and mechanisms of voluntary binge-like ethanol consumption: Examples, opportunities, and strategies for preclinical research.

Authors:  Brandon M Fritz; Stephen L Boehm
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2015-06-02       Impact factor: 5.067

3.  Baseline severity and the prediction of placebo response in clinical trials for alcohol dependence: A meta-regression analysis to develop an enrichment strategy.

Authors:  Bruno Scherrer; Julien Guiraud; Giovanni Addolorato; Henri-Jean Aubin; Andrea de Bejczy; Amine Benyamina; Wim van den Brink; Fabio Caputo; Maurice Dematteis; Anna E Goudriaan; Antoni Gual; Falk Kiefer; Lorenzo Leggio; Otto-Michael Lesch; Icro Maremmani; David J Nutt; François Paille; Pascal Perney; Roch Poulnais; Quentin Raffaillac; Jürgen Rehm; Benjamin Rolland; Nicolas Simon; Bo Söderpalm; Wolfgang H Sommer; Henriette Walter; Rainer Spanagel
Journal:  Alcohol Clin Exp Res       Date:  2021-08-21       Impact factor: 3.928

4.  Who achieves low risk drinking during alcohol treatment? An analysis of patients in three alcohol clinical trials.

Authors:  Katie Witkiewitz; Matthew R Pearson; Kevin A Hallgren; Stephen A Maisto; Corey R Roos; Megan Kirouac; Adam D Wilson; Kevin S Montes; Nick Heather
Journal:  Addiction       Date:  2017-06-26       Impact factor: 6.526

Review 5.  Guidelines for the Reporting of Treatment Trials for Alcohol Use Disorders.

Authors:  Katie Witkiewitz; John W Finney; Alex H S Harris; Daniel R Kivlahan; Henry R Kranzler
Journal:  Alcohol Clin Exp Res       Date:  2015-08-11       Impact factor: 3.455

Review 6.  Recommendations for the Design and Analysis of Treatment Trials for Alcohol Use Disorders.

Authors:  Katie Witkiewitz; John W Finney; Alex H S Harris; Daniel R Kivlahan; Henry R Kranzler
Journal:  Alcohol Clin Exp Res       Date:  2015-08-06       Impact factor: 3.455

Review 7.  Alcohol use disorder clinical course research: informing clinicians' treatment planning now and in the future.

Authors:  Stephen A Maisto; Megan Kirouac; Katie Witkiewitz
Journal:  J Stud Alcohol Drugs       Date:  2014-09       Impact factor: 2.582

8.  Acamprosate for treatment of alcohol dependence: mechanisms, efficacy, and clinical utility.

Authors:  Katie Witkiewitz; Kimber Saville; Kacie Hamreus
Journal:  Ther Clin Risk Manag       Date:  2012-02-01       Impact factor: 2.423

9.  Sodium oxybate for the maintenance of abstinence in alcohol-dependent patients: An international, multicenter, randomized, double-blind, placebo-controlled trial.

Authors:  Julien Guiraud; Giovanni Addolorato; Mariangela Antonelli; Henri-Jean Aubin; Andrea de Bejczy; Amine Benyamina; Roberto Cacciaglia; Fabio Caputo; Maurice Dematteis; Anna Ferrulli; Anna E Goudriaan; Antoni Gual; Otto-Michael Lesch; Icro Maremmani; Antonio Mirijello; David J Nutt; François Paille; Pascal Perney; Roch Poulnais; Quentin Raffaillac; Jürgen Rehm; Benjamin Rolland; Claudia Rotondo; Bruno Scherrer; Nicolas Simon; Katrin Skala; Bo Söderpalm; Lorenzo Somaini; Wolfgang H Sommer; Rainer Spanagel; Gabriele A Vassallo; Henriette Walter; Wim van den Brink
Journal:  J Psychopharmacol       Date:  2022-07-07       Impact factor: 4.562

10.  Clinically relevant characteristics associated with early treatment drug use versus abstinence.

Authors:  Gerald Cochran; Maxine Stitzer; Edward V Nunes; Mei-Chen Hu; Aimee Campbell
Journal:  Addict Sci Clin Pract       Date:  2014-04-04
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.